Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Apatinib

Oxaliplatin

Protein Kinase Inhibitors

Enzyme Inhibitors

An study of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.

250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.

Apatinib Mesylate

200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.

Camrelizumab

85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.

Jianping Xu, Master's Degree

This is a prospective, single-arm, single-center, clinical research.This trial will explore the efficacy and safety of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.

There is no high-level evidence on the efficacy of systemic therapy in neoadjuvant studies for hepatocellular carcinoma, and guidelines recommend TACE as the treatment of choice. Given that combination therapies such as immunotherapy in combination with targeted therapy and immunotherapy in combination with chemotherapy have achieved good efficacy in systemic therapy for liver cancer, this study is intended to explore the efficacy of TACE.

In this study, we propose to explore the use of kareliozumab in combination with apatinib and oxaliplatin for the treatment of hepatocellular carcinoma.

In this study, we propose to investigate the efficacy and safety of neoadjuvant therapy with kalilizumab in combination with apatinib and oxaliplatin in patients with potentially resectable hepatocellular liver cancer.

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

An Efficacy and Safety Study of Camrelizumab in Combination With Apatinib Mesylate and Oxaliplatin for Neoadjuvant Therapy in Patients With Potentially Resectable Hepatocellular Carcinoma.

The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period

Subjects underwent radical resection from the start until the date of the first documented tumor into recurrence or death from any cause, whichever occurred first

Time to disease progression or postoperative recurrence in subjects starting from radical postoperative resection, during the treatment period, and during the follow-up period

Including bleeding volume and prolonged hospital stay

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Associate Chief Physician

Lenvatinib

Tislelizumab

Chlorotrianisene

Participants will receive a combination treatment of Tislelizumab, Lenvatinib, and Transarterial Chemoembolization (TACE).

The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.

neoadjuvant therapy

Zhang Zhibo, PhD

In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative neoadjuvant therapy and postoperative adjuvant therapy. This study is a single-arm, prospective, exploratory clinical trial aimed at evaluating the effectiveness and safety of combining tislelizumab with transarterial chemoembolization (TACE) and lenvatinib as neoadjuvant therapy for resectable CNLC stage IIa-IIb HCC patients. The primary research endpoint of this study is recurrence-free survival (RFS). A total of 20 Chinese HCC patients with stage IIa-IIb and tumors deemed resectable by the investigator are enrolled in this study. For stage IIa patients, the inclusion criteria require meeting any of the following: unclear tumor boundaries, proximity to blood vessels, or suspicious residual margins. The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on comprehensive assessment of imaging results. Subsequently, tumor resection surgery is performed on eligible patients, followed by survival and safety follow-up for the patients.

1. Background

   Primary liver cancer is one of the most common malignancies worldwide, ranking sixth in terms of incidence and third in terms of cancer-related mortality. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, accounting for 85%-90% of cases. Treatment options for HCC include hepatectomy, transplantation, local ablation therapy, transarterial chemoembolization (TACE), radiation therapy, and systemic therapy. Hepatectomy is currently the preferred treatment for HCC, but the five-year recurrence rate after surgery is high, and the overall survival rate for early-stage HCC is relatively low. Therefore, improving the prognosis of HCC is of utmost importance.

   In recent years, there has been increasing exploration of surgical treatments for HCC, including neoadjuvant therapy and adjuvant therapy, to increase the R0 resection rate, reduce distant metastasis, and lower the risk of postoperative recurrence. Neoadjuvant therapy for HCC refers to interventions such as preoperative radiotherapy, interventional therapy, targeted therapy, immunotherapy, and portal vein embolization (PVE) administered to patients with resectable HCC who have a high risk of recurrence. These interventions aim to reduce liver inflammation, shrink tumors, and eliminate early-stage microlesions, thereby improving the curative resection rate and overall survival rate.

   However, there is limited research supporting neoadjuvant therapy for HCC, and its role in HCC treatment remains unclear. Neoadjuvant therapy has shown preliminary efficacy in various cancers, such as increasing resection rates and preserving sphincter function in colorectal cancer, demonstrating significant effects in early-stage non-small cell lung cancer and advanced malignant melanoma, and showing promise in resectable pancreatic cancer with high-risk factors. Previous explorations of neoadjuvant therapy for HCC have included hepatic artery chemotherapy, radiation therapy, and systemic therapy.

   With the emergence of immunotherapy and its promising efficacy in advanced liver cancer, research on immunotherapy as a neoadjuvant treatment has been conducted. Studies have shown that neoadjuvant treatment with immunotherapy in resectable liver cancer has achieved significant tumor necrosis and complete pathological responses. However, current clinical trials have not reached definitive conclusions, and the role of neoadjuvant therapy in patients with resectable HCC remains controversial. Therefore, this study aims to evaluate the efficacy and safety of Tislelizumab in combination with Transarterial Chemoembolization (TACE) and Lenvatinib as neoadjuvant therapy for patients with resectable CNLC stage IIa-IIb hepatocellular carcinoma (HCC), with the goal of providing a better treatment strategy to improve the survival outcomes of these patients.
2. Study Objectives

   2.1 Primary Objective:

   - To evaluate the recurrence-free survival (RFS) of patients with resectable CNLC stage IIa-IIb hepatocellular carcinoma (HCC) treated with Tislelizumab in combination with Transarterial Chemoembolization (TACE) and Lenvatinib as neoadjuvant therapy.

   2.2 Secondary Objectives:
   * To evaluate the objective response rate (ORR) of patients with resectable CNLC stage IIa-IIb HCC treated with Tislelizumab in combination with TACE and Lenvatinib as neoadjuvant therapy.
   * To evaluate the pathological complete response (pCR) rate of patients with resectable CNLC stage IIa-IIb HCC treated with Tislelizumab in combination with TACE and Lenvatinib as neoadjuvant therapy.
   * To evaluate the major pathological response (MPR) rate of patients with resectable CNLC stage IIa-IIb HCC treated with Tislelizumab in combination with TACE and Lenvatinib as neoadjuvant therapy.
   * To evaluate the R0 resection rates of patients with resectable CNLC stage IIa-IIb HCC treated with Tislelizumab in combination with TACE and Lenvatinib as neoadjuvant therapy.
   * To evaluate the overall survival (OS) of patients with resectable CNLC stage IIa-IIb HCC treated with Tislelizumab in combination with TACE and Lenvatinib as neoadjuvant therapy.
   * To assess the safety (according to NCI-CTCAE v5.0) of patients with resectable CNLC stage IIa-IIb HCC treated with Tislelizumab in combination with TACE and Lenvatinib as neoadjuvant therapy.
3. Study Design

   This is a single-arm, prospective, exploratory clinical trial aimed at investigating the effectiveness and safety of Tislelizumab combined with Transarterial Chemoembolization (TACE) and Lenvatinib as neoadjuvant therapy in approximately 20 patients with resectable CNLC stage IIa-IIb hepatocellular carcinoma (HCC) who have not received any prior treatment. Patients in CNLC stage IIa must meet one of the following criteria: unclear tumor margins, proximity to blood vessels, or suspicious residual margins. The primary endpoint of this study is recurrence-free survival (RFS), which will be assessed by the investigators based on the intention-to-treat (ITT) population assessment.

   Every effort will be made to ensure that the required tests and procedures outlined in the protocol are conducted according to plan. However, unforeseen circumstances may arise that are beyond the control of the investigators, making it difficult to perform the required assessments. In such cases, the investigators will take all necessary measures to ensure the safety and well-being of the participants. If a required assessment cannot be performed as specified in the protocol, the investigators will document the reasons for this occurrence. Additionally, any unexpected situations that occur will be promptly reported to the research team.

   3.1 Screening Period

   The investigators will enroll participants according to the following steps:

   3.1.1 Obtain informed consent with the participant's signature before conducting any study-related procedures.

   3.1.2 The principal investigator or designated personnel, who have undergone appropriate training, will review the inclusion/exclusion criteria to formally determine the eligibility of participants.

   3.2 Treatment Period

   During the treatment period, relevant physical examinations, laboratory tests, and collection of adverse events (AEs) and concomitant medication information will be conducted. The dispensing, retrieval, and inventory of medications will also be recorded.

   3.2.1 Neoadjuvant Stage
   * Tislelizumab: 200 mg, administered intravenously on the first day of each treatment cycle. Each cycle lasts for 3 weeks, with a total of 2 treatment cycles. The initial infusion (first day of the first cycle) should be completed within 60 minutes. If the infusion is well tolerated, subsequent infusions can be administered within 30 minutes, followed by an additional 2-hour patient monitoring period.
   * Lenvatinib: 8 mg per dose (for weight \<60 kg) or 12 mg per dose (for weight ≥60 kg), taken orally once daily until one week before surgery. The medication should be taken at the same fixed time each day, with or without food. The tablets should be swallowed whole. Alternatively, the tablet (without opening or crushing it) can be mixed with one tablespoon of water or apple juice in a glass to form a suspension. If a dose is missed and cannot be taken within 12 hours, it should be skipped, and the next dose should be taken at the regular scheduled time.
   * TACE: One session of TACE will be performed on the first day of the neoadjuvant treatment, within the first cycle. The conventional TACE (cTACE) technique will be used in this study.

   3.2.2 Surgical Stage

   After completing the neoadjuvant treatment, the feasibility of surgery will be assessed by the investigator. Surgery will be performed for tumor resection within 2-4 weeks after the neoadjuvant treatment. The investigator and pathology department will conduct an assessment of neoadjuvant treatment response (MPR and pCR).

   3.2.3 Postoperative Stage

   After the final treatment, patients will enter the treatment follow-up and safety monitoring period. Patients who discontinue treatment due to disease progression should continue to be followed up for their survival. Patients who discontinue treatment or exit the study for reasons other than disease progression will undergo tumor assessment every 12 weeks until disease progression, death, study completion, or intolerable toxicity. The investigator may collect information on the patient's survival (date of death and cause of death) and other anti-tumor treatments after the completion of the study by conducting telephone interviews with the patient, their family members, or local physicians. The details of each survival follow-up should be accurately recorded in the original medical records. Safety follow-up is required for all patients within 90 days after the last treatment.
4. Efficacy and Safety Assessment

The ITT population includes all enrolled patients and serves as the primary analysis population for efficacy. The safety population includes all patients who received at least one dose of the investigational drugs and will be used for safety analysis.

4.1 Efficacy Assessment

* Recurrence-Free Survival (RFS): The time from the first day of curative surgery to tumor recurrence or death from any cause.
* Objective Response Rate (ORR): The proportion of participants with the best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator according to RECIST v1.1 during the neoadjuvant stage.
* Pathological Complete Response Rate (pCR): The proportion of patients assessed by the investigator, after completion of neoadjuvant treatment, with no residual tumor cells in the resected tumor.
* Major Pathological Response Rate (MPR): The proportion of patients assessed by the investigator, after completion of neoadjuvant treatment, with ≤10% residual viable tumor cells in the resected tumor.
* R0 Resection Rate: The proportion of patients achieving R0 resection among all surgical patients.
* Overall Survival (OS): The time from the start of treatment to death from any cause.

4.2 Safety Assessment

Safety will be evaluated by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs) in terms of their incidence and severity, graded according to NCI-CTCAE v5.0. Laboratory test results (such as hematology, clinical chemistry, urine analysis), vital signs, ECOG performance status, and physical examinations will also be used to assess safety. Descriptive statistics will be used to analyze all safety data in the safety population.

A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

A Single-arm Exploratory Clinical Study of Tislelizumab Combined With Transarterial Chemoembolization (TACE) and Lenvatinib in the Neoadjuvant Treatment of Resectable CNLC Stage Ⅱa-Ⅱb Hepatocellular Carcinoma

The period of time from the first day of curative surgery until tumor recurrence or death from any cause.

The proportion of participants assessed by the investigators based on RECIST v1.1 criteria, who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) during the neoadjuvant treatment period.

The proportion of patients evaluated by the investigators after completion of neoadjuvant treatment, who have no residual tumor cells in the resected tumor.

The proportion of patients assessed by the investigators after completion of neoadjuvant treatment, who have residual viable tumor cells of ≤10% in the resected tumor.

The proportion of patients who achieve R0 resection among all surgical patients.

The time from the start of treatment to death from any cause.

First Affiliated Hospital of Fujian Medical University

Director of Hepatobiliary and Pancreatic Surgery Department

Rare Diseases

Primary Liver Cancer

Micronutrients

Hematinics

Anti-Infective Agents

Vitamins

Leucovorin

Fluorouracil

Doxorubicin

Liposomal doxorubicin

Raltitrexed

Cisplatin

Liver Extracts

Anti-Bacterial Agents

Antibiotics, Antitubercular

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folic Acid Antagonists

Folate

Vitamin B9

Folinic Acid

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.

The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.

130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Lobaplatin

50 mg per square body surface area was used for monthly transhepatic arterial infusions.

Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.

infusions

Oxaliplatin, Leucovorin, fluorouracil

Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Lobaplatin, Raltitrexed

Mingxin Pan, Prof.

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected

#excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results, and the control group received postoperative conventional treatment combined with empirical transarterial chemoembolization with Doxorubicin.

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled Trial

The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year.

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Zhujiang Hospital

Pierce Chow, MD, PhD

Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition. The researchers describe the use of the "metro ticket" approach to analyze surgical outcomes over the whole spectrum of anatomically resectable HCC to define overall survival including intermediate stage tumors (BCLC B). The analysis the researchers provide in this study enables the clinician to select the optimal surgical resection candidate based on robust long term survival data.

In addition, study compares outcome for open surgery vs laparoscopic surgery, survival outcome for viral and non-viral HCC using Albumin-Bilirubin (ALBI) for more comprehensive study result.

Patients who underwent surgical resection (both open surgery and laparoscopic surgery) for HCC from 1st January 2000 to 30th June 2018 by the joint hepato-pancreato-biliary surgery service at the Singapore Healthcare Group of Hospitals (Singapore General Hospital and the National Cancer Centre Singapore) were retrospectively identified from a prospectively kept institutional database.

The assessment of the size, number of nodules and vascular invasion of HCC were based on pre-operative CT/MRI imaging and pathological assessment of the resected specimens. All resections were histologically confirmed as HCC. Patients with macrovascular invasion and extrahepatic invasion were excluded from analysis as were patients resected for other palliative intents (e.g. ruptured HCC).

Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC

Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC: a Metroticket Approach

Time between the respective surgery to the time of death. Bivariate contour plots of 5-year survival probability as a function of X = AFP concentration (ng/mL) and Y = tumor burden index (size of largest nodule + 2\*number of nodules) (TBI) were obtained as smoothed contours originating from an empirically-derived bivariate 5-year survival distribution S(X,Y)=1- F(x ≤X,y ≤Y). The function F(x ≤X,y ≤Y) is the empirical, bivariate cumulative distribution of 5-year mortality as a function of X and Y defined over the domain (0\<X≤5000,1≤Y≤15) in our patient cohort. All patients in our study cohort were followed up for at least 5 years following respective surgery which allowed estimation of actual all-cause 5-year mortality.

The metro ticket modeling was based on tumour size and number of nodules extracted at pre-operative radiological imaging and post surgical pathology assessment. Continuous variables are summarized as mean, standard deviation, 25th and 75th percentiles, median and minimum and maximum. Categorical variables are summarized as counts (N) and percentages (%).

Bland-Altman analysis, which is based on a simple but effective graphical approach for evaluating bias and for calculating bounds on the expected magnitude of the individual differences arising between the two measurement methods, is used. A 45° line of identity with scatter plot was produced to display the correlation between the 2 measurements. Bias was evaluated by calculating (d) ̅ the mean difference of the measurements. Limits of agreement, calculated as (d) ̅ ±2sd , where sd is the standard deviation of the individual differences, defined bounds within which 95% of the measurement differences are expected to fall. The B-A plot defines the limits of agreements. B-A analysis is performed using TBI over a wide range, 0 ≤ TBI ≤ 30, and a restricted range focusing on small tumors, 0 \< TBI ≤ 6.

Singapore General Hospital

National Cancer Centre, Singapore

Symptoms and General Pathology

Recurrence

Neoplasm, Residual

Disease Attributes

Patient with hepatocellular carcinoma who can undergo radical resection

blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma

circulating tumor DNA

Cheng Zhang

Weichao Liang, Prof.

Weichao Liang

Cheng Zhang, Dr.

Mingxin Pan

Yinbing Wu, Prof.

Junming He, Prof.

Weidong Wang, Prof.

Rongping Guo, Prof.

Qingsong Wu, Prof.

This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.

The recurrence rate of hepatocellular carcinoma after curative treatment is high, and the minimal residual disease(MRD) in patients is the major cause of liver cancer recurrence, and the MRD is an important basis for the decision of adjuvant therapy after curative treatment. Previous studies have confirmed that circulating tumor DNA(ctDNA)-MRD monitoring model can accurately predict the recurrence of hepatocellular carcinoma patients. It was also found in retrospective analysis that tumor free survival was significantly prolonged after ctDNA-positive treatment for hepatocellular carcinoma after resection. This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.This study is to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence.

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring Minimal Residual Disease Based on Circulating Tumor DNA

percentage of recurrence-free survival 2 years after surgery

Correlation between ctDNA-MRD status dynamic changes and relapse

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin	NCT04850040	Hepatocellular ...	Apatinib Mesyla... Camrelizumab Oxaliplatin	18 Years - 70 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC	NCT06003673	Hepatocellular ...	neoadjuvant the...	18 Years - 75 Years	First Affiliated Hospital of Fujian Medical University
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial	NCT05766605	Hepatocellular ...	Oxaliplatin Doxorubicin Lobaplatin Cisplatin Oxaliplatin, Le... Lobaplatin, Ral...	18 Years - 75 Years	Zhujiang Hospital
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin	NCT04850040	Hepatocellular ...	Apatinib Mesyla... Camrelizumab Oxaliplatin	18 Years - 70 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC	NCT06294808	Hepatocellular ...		21 Years - 80 Years	National Cancer Centre, Singapore
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC	NCT06294808	Hepatocellular ...		21 Years - 80 Years	National Cancer Centre, Singapore
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin	NCT04850040	Hepatocellular ...	Apatinib Mesyla... Camrelizumab Oxaliplatin	18 Years - 70 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA	NCT06157060	Hepatocellular ...	circulating tum...	18 Years - 75 Years	Zhujiang Hospital

Spots Global Cancer Trial Database for hepatocellular carcinoma resectable